New triazolothiadiazole and triazolothiadiazine derivatives as kinesin Eg5 and HIV inhibitors: synthesis, QSAR and modeling studies

Abstract

Abstract A new series of fused 1,2,4-triazoles, namely 6-aryl-3-(furan-2-yl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles 3a–h and 4a–f as well as 6-aryl-3-(furan-2-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines 5a–h, were synthesized by the condensation of 4-amino-5-(furan-2-yl)-4H-1,2,4-triazole-3-thiol (2) with substituted aromatic acids and phenacyl bromides, respectively. The structures of the newly synthesized compounds were established using spectroscopic analysis, while that of 3e was confirmed independently by a single-crystal X-ray structure determination. The compounds were evaluated for their antiviral activity against the replication of HIV-1 and HIV-2 in MT-4 cells using an MTT assay. In a docking study, 4b interacted with several amino acids in the reverse transcriptase (RT) binding site of HIV-1. Some new analogues were selected for evaluation of their Eg5 inhibitory activity using an in vitro malachite green ATPase assay. The QSAR of these new analogues was studied as well.